Patents Assigned to Genzyme Corporation
  • Combination therapy for treating breast cancer
    Patent number: 9539325
    Abstract: The invention provides compositions and methods for treating breast cancer. Specifically, the invention relates to administering a Transforming Growth Factor beta (TGF?) antagonist in combination with capecitabine and ixabepilone to treat breast cancer.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: January 10, 2017
    Assignee: Genzyme Corporation
    Inventors: Jay Harper, Scott Lonning, Frank Hsu
  • Method of lowering blood glucose
    Patent number: 9532976
    Abstract: The invention provides methods of treating a diabetic subject comprising administering a glucosylceramide synthase inhibitor to the subject.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: January 3, 2017
    Assignee: Genzyme Corporation
    Inventors: Seng H. Cheng, Nelson S. Yew, Ronald K. Scheule, Hongmei Zhao
  • Methods for producing preparations of recombinant AAV virions substantially free of empty capsids
    Patent number: 9528126
    Abstract: Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.
    Type: Grant
    Filed: February 7, 2012
    Date of Patent: December 27, 2016
    Assignee: Genzyme Corporation
    Inventors: Guang Qu, John Fraser Wright
  • Salt forms of (S)-quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate
    Patent number: 9518049
    Abstract: The present invention relates to novel salt forms of (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate useful as an inhibitor of glucosylceramide synthase (GCS) and for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: December 13, 2016
    Assignee: GENZYME CORPORATION
    Inventors: Craig S. Siegel, Jin Zhao
  • AAV virions with decreased immunoreactivity and uses therefor
    Patent number: 9506083
    Abstract: Methods of making and using recombinant AAV virions with decreased immunoreactivity are described. The recombinant AAV virions include mutated capsid proteins or are derived from non-primate mammalian AAV serotypes and isolates that display decreased immunoreactivity relative to AAV-2.
    Type: Grant
    Filed: July 9, 2007
    Date of Patent: November 29, 2016
    Assignee: Genzyme Corporation
    Inventors: Alejandra Elena Arbetman, Peter C. Colosi, Michael A. Lochrie, Richard T. Surosky
  • Targeting of glycoprotein therapeutics
    Patent number: 9498518
    Abstract: Methods of making ligand-decorated polymer conjugates of therapeutic glycoproteins are described. Improved targeting of glycoproteins to specific tissues is achieved by masking the natural carbohydrate and other surface determinants with high molecular weight polymers, such as, e.g., PEG, polysialic acid, etc., which in turn are decorated with target-specific ligands. In some embodiments, acid-labile linkages in such conjugates or rapidly degradable masking groups allow for the intracellular release of the polymer from the glycoprotein, for example, under conditions found in lysosomes.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: November 22, 2016
    Assignee: GENZYME CORPORATION
    Inventor: James Stefano
  • Treatment of multiple sclerosis (MS)
    Patent number: 9498528
    Abstract: A method for treatment of multiple sclerosis (MS) with Campath-1H with significant efficacy and a favorable safety profile is described, which offers an acceptable benefit/risk ratio. Especially described is the use of Campath-1H (alemtuzumab) for the production of a medicament for the treatment of multiple sclerosis (MS), comprising a first treatment cycle followed by at least one further treatment cycle of Campath-1H (alemtuzumab), in which each treatment cycle comprises 1-5 daily doses which are applied on consecutive days, wherein the daily dose is >0 and ?12 mg, and wherein each treatment cycle is separated from the next cycle by at least 1-24 months. Also described are treatment regimens comprising the administration of less than 12 mg/day of Campath-1H for a period of 1-5 consecutive days.
    Type: Grant
    Filed: September 10, 2007
    Date of Patent: November 22, 2016
    Assignees: GENZYME CORPORATION, ALCAFLEU MANAGEMENT GMBH & CO. KG.
    Inventors: David H. Margolin, Walter Hong, Alasdair J. Coles, Alastair Compston, Ze'ev Shaked
  • Methods of treating Parkinson's disease using viral vectors
    Patent number: 9492415
    Abstract: Methods of delivering viral vectors, particularly recombinant adeno-associated virus (rAAV) virions, to the central nervous system (CNS) using convection enhanced delivery (CED) are provided. The rAAV virions include a nucleic acid sequence encoding a therapeutic polypeptide. The methods can be used for treating CNS disorders such as for treating Parkinson's Disease.
    Type: Grant
    Filed: October 8, 2012
    Date of Patent: November 15, 2016
    Assignees: Genzyme Corporation, The Regents of the University of California
    Inventors: Krystof Bankiewicz, Janet Cunningham
  • Oligosaccharide-protein conjugates
    Patent number: 9493498
    Abstract: Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: November 15, 2016
    Assignee: GENZYME CORPORATION
    Inventors: Luis Z. Avila, Clark Q. Pan, Patrick Finn, John Harrahy, Qun Zhou, Yunxiang Zhu, Paul A. Konowicz, Duncan E. Paterson, Andreas Peer, Joseph P. Kutzko, Michael R. Reardon, James E. Stefano, Xiaoyang Zheng, Robert J. Miller, Lauren Young
  • VEGF ANTAGONIST COMPOSITIONS AND USES THEREOF
    Publication number: 20160326501
    Abstract: The invention provides compositions and methods for treating a disease or disorder associate with vascular endothelial growth factor (VEGF). Specifically, the invention relates to an oligomerized VEGF binding domain to provide VEGF antagonism, and thereby treat diseases associated thereof.
    Type: Application
    Filed: July 25, 2016
    Publication date: November 10, 2016
    Applicant: Genzyme Corporation
    Inventors: James Stefano, Clark Pan, Huawei Qui, Michael O'Callaghan, Gloria Matthews
  • Antibodies to TGF-?
    Patent number: 9481726
    Abstract: The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGF?), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralize TGF?1, TGF?2 and TGF?3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: November 1, 2016
    Assignee: GENZYME CORPORATION
    Inventors: Steven R. Ledbetter, Celia Patricia Hart, Robert G. Holgate, Lutz U. Jermutus, Catriona L. Buchanan, Alexander R. Duncan, Donna K. Finch
  • Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
    Patent number: 9481671
    Abstract: A method of treating a glomerular disease selected from the group consisting of mesangial proliferative glomerulonephritis, collapsing glomerulopathy, proliferative lupus nephritis, crescentic glomerulonephritis and membranous nephropathy in a subject comprises administering to the subject an effective amount of a glucosylceramide synthase inhibitor.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: November 1, 2016
    Assignee: Genzyme Corporation
    Inventors: Oxana Ibraghimov-Beskrovnaya, Thomas A. Natoli
  • Oligosaccharides comprising an aminooxy group and conjugates thereof
    Patent number: 9469850
    Abstract: The invention provides methods for the synthesis of oligosaccharides comprising an aminooxy group. The invention further provides oligosaccharides comprising an aminooxy group, methods for coupling oligosaccharides comprising an aminooxy group to glycoproteins, and oligosaccharide-protein conjugates. Also provided are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-protein conjugate.
    Type: Grant
    Filed: May 8, 2014
    Date of Patent: October 18, 2016
    Assignee: Genzyme Corporation
    Inventors: Yunxiang Zhu, Seng H. Cheng, Canwen Jiang, Luis Z. Avila
  • STEPPED CANNULA
    Publication number: 20160296694
    Abstract: Described herein are cannulas having a stepped exterior. Also described are methods of making and using these cannulas, for example to deliver one or more materials to the central nervous system of an animal.
    Type: Application
    Filed: February 26, 2016
    Publication date: October 13, 2016
    Applicants: Genzyme Corporation, The Regents of the University of California
    Inventors: Krystof Bankiewicz, Jurg M. Sommer
  • Device for viral inactivation of liquid media
    Patent number: 9441196
    Abstract: An apparatus (100) capable of viral inactivation of liquid media includes at least one coaxial cylinder (110) constructed of an outer cylinder (120) and an inner cylinder (130), a liquid media inlet (140), at least one emitter of type C ultraviolet radiation (145), and a liquid media outlet (150). The inner cylinder has an outer diameter adapted to form a gap (160) between the outer diameter of the inner cylinder and the inner diameter of the outer cylinder. The media flows in a substantially cyclonic flow path along the gap. The at least one emitter of type C ultraviolet radiation is placed inside the inner cylinder. The outlet is connected to the outer cylinder at, or proximal to, an end of the outer cylinder opposite the inlet.
    Type: Grant
    Filed: June 6, 2011
    Date of Patent: September 13, 2016
    Assignee: Genzyme Corporation
    Inventor: Muthukumar Dhanasekharan
  • VEGF antagonist compositions and uses thereof
    Patent number: 9441029
    Abstract: The invention provides compositions and methods for treating a disease or disorder associated with vascular endothelial growth factor (VEGF). Specifically, the invention relates to an oligomerized VEGF binding domain to provide VEGF antagonism, and thereby treat diseases associated thereof.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: September 13, 2016
    Assignee: Genzyme Corporation
    Inventors: James Stefano, Clark Pan, Huawei Qiu, Michael O'Callaghan, Gloria Matthews
  • METHODS OF TREATING PARKINSON'S DISEASE USING VIRAL VECTORS
    Publication number: 20160256534
    Abstract: Methods of delivering viral vectors, particularly recombinant adeno-associated virus (rAAV) virions, to the central nervous system (CNS) using convection enhanced delivery (CED) are provided. The rAAV virions include a nucleic acid sequence encoding a therapeutic polypeptide. The methods can be used for treating CNS disorders such as for treating Parkinson's Disease.
    Type: Application
    Filed: March 25, 2016
    Publication date: September 8, 2016
    Applicants: Genzyme Corporation, The Regents of the University of California
    Inventors: Krystof Bankiewicz, Janet Cunningham
  • Gene therapy for neurodegenerative disorders
    Patent number: 9415119
    Abstract: Compositions and methods for treating disorders affecting motor function, such as motor function affected by disease or injury to the brain and/or spinal cord, are disclosed.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: August 16, 2016
    Assignee: GENZYME CORPORATION
    Inventors: Marco A. Passini, Lamya Shihabuddin, Seng H. Cheng
  • Plunger and finger grip for a syringe
    Patent number: D775324
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: December 27, 2016
    Assignee: GENZYME CORPORATION
    Inventors: Robin Cameron Larson, Barbara Yu-Fong Wan, Daniel John Zuniga, Manikandan Namasivayam, Leticia Fabiano, Frederic Daniel Blanquaert, Anthony John Franchino, Jr.
  • Plunger and finger grip for a syringe
    Patent number: D775325
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: December 27, 2016
    Assignee: GENZYME CORPORATION
    Inventors: Robin Cameron Larson, Barbara Yu-Fong Wan, Daniel John Zuniga, Manikandan Namasivayam, Leticia Fabiano, Frederic Daniel Blanquaert, Anthony John Franchino, Jr.